Aquestive Therapeutics
AQST
57 hedge funds and large institutions have $90M invested in Aquestive Therapeutics in 2020 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 9 closing their positions.
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
157% more capital invested
Capital invested by funds: $35M → $90M (+$54.9M)
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
36% more funds holding
Funds holding: 42 → 57 (+15)
24% more call options, than puts
Call options by funds: $671K | Put options by funds: $542K
7.55% more ownership
Funds ownership: 47.58% → 55.13% (+7.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$8.06M |
| 2 |
BlackRock
New York
|
+$5.59M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.33M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$877K |
| 5 |
Squarepoint
New York
|
+$817K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.86M |
| 2 |
DCM
DG Capital Management
New York
|
-$1.2M |
| 3 |
EP
Eversept Partners
New York
|
-$657K |
| 4 |
Renaissance Technologies
New York
|
-$644K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$454K |
AQST Hedge Fund Activity: Q2 2020 in Review
57 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2020, worth a combined $90M — up 157% from $35M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new AQST positions and 9 closed out — a net gain of 16 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $8.06M. The largest seller was JP Morgan Chase, cutting an estimated $1.86M.
- 57 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2020, up from 42 in Q1 2020.
- Funds reported $90M of Aquestive Therapeutics stock for Q2 2020, up 157% quarter-over-quarter.
- 25 funds opened new Aquestive Therapeutics positions in Q2 2020 and 9 closed out, a net change of +16 holders.
- The largest Aquestive Therapeutics buyer in Q2 2020 was Perceptive Advisors, an estimated $8.06M added.
- The largest Aquestive Therapeutics seller in Q2 2020 was JP Morgan Chase, an estimated $1.86M sold.
Based on aggregated 13F filings for Q2 2020.